Categories
Change Password!
Reset Password!
The PAtient preferences stUdy in inSomnia (PAUSe) sub-study previously utilized a discrete choice experiment (DCE) to evaluate treatment preferences among chronic insomnia people enrolled in randomized, placebo-controlled clinical trials.
Patients with chronic insomnia prioritize treatments that improve daytime functioning and minimize withdrawal effects, with most preferring treatment over no treatment.
The PAtient preferences stUdy in inSomnia (PAUSe) sub-study previously utilized a discrete choice experiment (DCE) to evaluate treatment preferences among chronic insomnia people enrolled in randomized, placebo-controlled clinical trials. To validate these findings in a broader setting, researchers conducted the PAUSe II replication study involving real-world patients with self-reported insomnia recruited through online panels. The objective was to compare treatment preferences between real-world patients and those participating in clinical trials.
Participants completed a DCE in which they selected between insomnia treatment options characterized by varying benefits and risks. Unlike the original PAUSe study, 20% of participants in the real-world cohort were randomly assigned a version of the DCE that encompassed an option to decline treatment (“opt out”). Researchers used a mixed logit model for estimating relative attribute importance (RAI) and determine the trade-offs patients were willing to make between treatment benefits and potential risks.
Among the real-world group (n=474), the real-world opt-out subgroup (n=131), and the clinical trial population (n=602), the strongest drivers of treatment preference were found to be improvement in daytime functioning and avoidance of withdrawal symptoms. The RAI for enhanced daytime functioning was 29.7%, 23.3%, and 33.6% across the respective groups, while prevention of withdrawal symptoms accounted for 33.5%, 23.3%, and 27.3%. Participants who were offered the opt-out choice still showed a clear preference for receiving treatment rather than no treatment.
Despite some variation between real-world and trial populations, patients with insomnia consistently prioritized therapies that enhance daytime performance while minimizing the risk of medication withdrawal effects.
Sleep Science and Practice
Patient preferences for the benefits and risks of insomnia medication in a clinical trial and real-world setting
Andrea Phillips Beyer et al.
Comments (0)